Abstract 144P
Background
Fluid cytology may provide false-negative or false-positive results, partly due to reactive cells mimicking malignant cells. This study aims to evaluate the utility of body fluids as source for detecting actionable molecular alterations associated with malignancy.
Methods
ctDNA derived from cerebrospinal (CSF) (n=7), pleural (n=10), and ascitic (n=24) fluids collected from 41 pts. with various malignancies, including lung (11), breast (8), ovary (8), pancreas (4), and others (10), were analyzed for detection of pathogenic molecular alterations using NGS. Concordant analysis body fluid (n=24) and tissue (n=9) was conducted in a subset.
Results
Pathogenic fluid ctDNA findings were observed in 78% (32/41) of samples. Potentially actionable alterations were observed in genes such as KRAS, BRAF, NRAS, PIK3CA and EGFR. Table: 144P
ESCAT categorization of variants in body fluids
Variant tier category | Number of variants | Number of samples |
IA | 16 | 13 (41%) |
IC | 2 | 2 (6%) |
IIIA | 9 | 6 (19%) |
IIIB | 1 | 1 (2%) |
IVA | 5 | 4 (12%) |
IVB | 1 | 1 (2%) |
X | 20 | 17 (53%) |
Simultaneous analysis of tissue and fluid samples in 9 cases showed concordant findings in 67% (6/9) samples. Unique molecular alterations were observed in 4 fluid samples (not found in the tissue), providing potentially valuable insights into molecular heterogeneity. In the simultaneous body fluid and blood analysis (n=24), 30 variants were detected. Of these, 14 variants were detected in both sample types whereas 3 were missed in fluid. The most relevant finding was presence of 13 unique variants in body fluids (not found in blood liquid biopsy). Out of 13 samples with available fluid cytology, 7 samples showed both cytology positivity for malignancy and ctDNA. From the remaining 6 cytology-negative samples, 4 were positive for ctDNA, potentially demonstrating the utility of fluid molecular profiling for establishing malignant involvement.
Conclusions
This study emphasizes potential of fluid ctDNA profiling to detect pathogenic molecular alterations, providing insights into potentially actionable targets and the presence of malignancy. Validation in larger cohorts is warranted.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
Datar Cancer Genetics.
Funding
Has not received any funding.
Disclosure
S. Limaye, A.K. Vaid, T. Crook, A. Gaya, R. Kurzrock: Non-Financial Interests, Personal, Advisory Board: Datar Cancer Genetics. D.S. Patil: Financial Interests, Personal, Full or part-time Employment: Datar Cancer Genetics. All other authors have declared no conflicts of interest.
Resources from the same session
4P - Predicting triple-negative breast cancer molecular subtype from hematoxylin and eosin using deep neural networks
Presenter: Nicola Occelli
Session: Cocktail & Poster Display session
Resources:
Abstract
5P - Onconaut: A precision medicine platform for oncology therapies
Presenter: Altuna Akalin
Session: Cocktail & Poster Display session
Resources:
Abstract
6P - Diagnostic accuracy of artificial intelligence in classifying HER2 status in breast cancer immunohistochemistry slides: A systematic review and meta-analysis
Presenter: Daniel Arruda Navarro Albuquerque
Session: Cocktail & Poster Display session
Resources:
Abstract
8P - Precision medicine drug testing platform to guide the treatment of EML4-ALK fusion lung cancers
Presenter: Sofia Merajver
Session: Cocktail & Poster Display session
Resources:
Abstract
9P - Circulating tumor cells and circulating tumor DNA detection in colorectal cancer stage III patients receiving three or six months of adjuvant treatment
Presenter: Asimina Koulouridi
Session: Cocktail & Poster Display session
Resources:
Abstract
10P - Novel theranostic agents in non-metastatic Egyptian breast cancer patients: miR-96, miR-1275, miR-4317 and miR-744
Presenter: Ahmed Mokhtar
Session: Cocktail & Poster Display session
Resources:
Abstract
11P - A prospective study to evaluate the prognostic implications and molecular mechanism of SLC40A1 gene in primary acute myeloid leukemia
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
12P - Prognostic value of PD-L1 expression and neutrophil-to-lymphocyte ratio to neoadjuvant chemo-immunotherapy in muscle-invasive urothelial carcinoma patients from the AURA trial
Presenter: Jeremy Blanc
Session: Cocktail & Poster Display session
Resources:
Abstract
13P - Methylation of BRCA1 and RAD51C promoters determined by droplet digital PCR predicts homologous repair deficiency in patients with high-grade serous ovarian cancer: Results of the BOVARY-pilot study in paired FFPE and plasma samples and the ICL ovarian cohort
Presenter: Cassandra Michel
Session: Cocktail & Poster Display session
Resources:
Abstract
14P - SLFN11 detection in patients with small cell lung cancer treated with lurbinectedin: A retrospective translational analysis
Presenter: Daniela Scattolin
Session: Cocktail & Poster Display session
Resources:
Abstract